The Office of the State Council issued an Opinion on Reforming and Perfecting Policies Supply and Use of Generic Drugs on 21 March 2018. This is a policy paper, and therefore no concrete implementations were mentioned. However, there are certain articles in this Opinion that could raise eyebrows with pharmaceutical multinationals, as follows:
1. Cross-departmental sharing mechanism for drug production and usage information shall be established. This is for publishing drug supply and demand situation to guide enterprises for research and development, registration and production.
2. Generics of drugs with short supply, for the prevention and treatment of major infectious diseases and rare diseases, for public health emergencies, drugs for children, and drugs within one year prior to its patent expiration date but no application for drug registration shall be encouraged.
3. Anti-monopoly law enforcement in the IPRs field shall be strengthened to prevent abuse of IPRs to promote generic drugs. The Opinion also stated at the same time drug innovation should receive sufficient protection.
4. An early warning mechanism shall be established to reduce patent infringement risk of generic drug enterprises.
5. Research and development on pharmaceutical raw excipient materials and packaging materials shall be improved.
6. Efficiency of launching, examination and approval of generic drugs shall be improved. Applications for registration of generic drugs compulsorily licensed by the State, drugs listed in the catalogue of encouraged generic drugs, generic drugs supported by Major National Science and Technology Projects shall be given priority for examination and approval.
7. Illegal activities such as faking data, cheating on materials, adulterating and so on shall be seriously investigated and punished, accountability shall be strengthened, investigation and punishment results shall be revealed to the public.
8. The centralized drug purchasing agency shall:
·Draft procurement catalogue based on drug generic name.
·Promote fair competition between generic drugs having the same quality and efficacy with those of original drugs.
·Prepare procurement codes for public medical hygiene institutes for newly approved generic drugs in good time.
·Start purchasing procedures of drugs with generic names already listed in the drug procurement catalogue in good time.
·Start discussions on drugs with generic names not listed in the drug procurement catalogue in good time to initiate inclusion into the drug procurement catalogue from the date of approval.
·Unconditionally include drugs with compulsorily licences by the China National Intellectual Property Administration (CNIPA, formerly SIPO) in all local drug procurement catalogues.
9. Generic drugs having the same quality and efficacy as those of original drugs shall be included in the catalogue of mutually replaceable drugs.
10. Only in special circumstances can commercial product names be used on prescriptions.
11. Payments to generic drugs having the same quality and efficacy with those of original drugs and original drugs shall be the same.
12. Drugs in the basic medical insurance drug catalogue shall not be limited according to commercial product name or manufacturer. Medical insurance information system shall be updated in good time to ensure approved generic drugs to be equally included within scope of medical insurance payment.
13. Research and development expenses of generic drugs enterprises for developing new technologies, new products, new processes, if eligible, may be additionally deducted prior to corporate income tax deduction in accordance with relevant provisions. Where a generic drugs enterprise is identified as high-tech enterprise, its corporate income tax is reduced to 15%.
We will have to wait and see how and when the above would be implemented. However, the following points are interesting to me:
·Raw excipient materials and packaging materials are specifically encouraged. I am not sure of the reason, but maybe because Chinese manufacturers are good at these?
·Issues of faking data, cheating on materials, adulterating and so on are real issues recognised by the Chinese government and will be taken seriously.
·Unconditional inclusion of drugs with compulsory license from CNIPA in all local drug procurement catalogues may raise interest for generics to obtain compulsory license, even though there is no grant of compulsory license by CNIPA. Would this change the landscape, making China more like India in this respect?
·The Opinion has various specific measures to discourage the use of commercial product name, including those in (8), (10), and (12). It appears that the Chinese government wishes to dissociate a drug from a commercial product name. Would this affect the trade mark strategy of pharmaceutical companies1?
Author: Toby Mak
http://www.teehowe.com/download/CIPA-2019-02 generic drugs.pdf